VivoSim Labs Inc (VIVS)

VivoSim Labs Inc. is a healthcare company focused on biotechnology services, with an emphasis on testing drugs and drug candidates in 3D human tissue models of the liver and intestine. The company supports pharmaceutical and biotechnology partners with liver and intestinal toxicology insights through its new approach methodologies (NAM) models, as well as customized services for investigational toxicology, mechanism-of-action studies, and related applications of complex human tissue models. It also provides liver toxicology predictive screening and research services, and studies intestinal side effect profiles for therapeutic candidates at different stages of development. VivoSim Labs uses proprietary technologies to create functional 3D human tissues that replicate important features of native tissue structure and function, and it develops human normal and disease models using high-throughput systems, bioprinted systems, and flow- and stretch-capable 3D platforms. The company was incorporated in 2007 and is headquartered in San Diego, California. It was formerly known as Organovo Holdings, Inc. and adopted the VivoSim Labs, Inc. name in April 2025.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.